These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 21308526)
21. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547 [TBL] [Abstract][Full Text] [Related]
22. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Monath TP; McCarthy K; Bedford P; Johnson CT; Nichols R; Yoksan S; Marchesani R; Knauber M; Wells KH; Arroyo J; Guirakhoo F Vaccine; 2002 Jan; 20(7-8):1004-18. PubMed ID: 11803060 [TBL] [Abstract][Full Text] [Related]
23. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China. Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of environment safety of a Japanese encephalitis live attenuated vaccine. Liu X; Jia L; Nie K; Zhao D; Na R; Xu H; Cheng G; Wang J; Yu Y; Li Y Biologicals; 2019 Jul; 60():36-41. PubMed ID: 31178277 [TBL] [Abstract][Full Text] [Related]
25. Investigation of immune response induction by Japanese encephalitis live-attenuated and chimeric vaccines in mice. Fang E; Liu X; Liu X; Li M; Wang L; Li M; Zhang Z; Li Y; Yu Y MedComm (2020); 2022 Jun; 3(2):e117. PubMed ID: 35415706 [TBL] [Abstract][Full Text] [Related]
26. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690 [TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481 [TBL] [Abstract][Full Text] [Related]
29. The Potential Use of Wolbachia-Based Mosquito Biocontrol Strategies for Japanese Encephalitis. Jeffries CL; Walker T PLoS Negl Trop Dis; 2015; 9(6):e0003576. PubMed ID: 26086337 [TBL] [Abstract][Full Text] [Related]
30. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Erra EO; Kantele A Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529 [TBL] [Abstract][Full Text] [Related]
31. Japanese encephalitis vaccine in travelers. Jelinek T Expert Rev Vaccines; 2008 Jul; 7(5):689-93. PubMed ID: 18564023 [TBL] [Abstract][Full Text] [Related]
32. Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies. Ginsburg AS; Meghani A; Halstead SB; Yaich M Hum Vaccin Immunother; 2017 Oct; 13(10):2222-2231. PubMed ID: 28841362 [TBL] [Abstract][Full Text] [Related]
33. Product review on the JE vaccine IXIARO. Firbas C; Jilma B Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812 [TBL] [Abstract][Full Text] [Related]
34. Japanese encephalitis vaccine: need of the hour in endemic states of India. Verma R Hum Vaccin Immunother; 2012 Apr; 8(4):491-3. PubMed ID: 22370517 [TBL] [Abstract][Full Text] [Related]
35. Development of a recombinant vaccine against Japanese encephalitis. Kaur R; Vrati S J Neurovirol; 2003 Aug; 9(4):421-31. PubMed ID: 12907387 [TBL] [Abstract][Full Text] [Related]
36. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. Yang D; Li XF; Ye Q; Wang HJ; Deng YQ; Zhu SY; Zhang Y; Li SH; Qin CF Vaccine; 2014 May; 32(23):2675-81. PubMed ID: 24709585 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323 [TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children. Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242 [TBL] [Abstract][Full Text] [Related]
40. Japanese Encephalitis Among Three U.S. Travelers Returning from Asia, 2003-2008. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2009 Jul; 58(27):737-40. PubMed ID: 19609246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]